Table 4 Summary of literatures on SBRT boost in patients ineligible for BT

Albuquerque et al. (2019)

15 LACC

28/4

139

n/a

26.7% G3 rectal ulcer/fistula

2-yr LC 70.1%

2-yr PFS 46.7%

2-yr OS 53.3%

Kubicek et al. (2013)

3 recurrent cervical cancer;

4 LACC;

2 endometrial cancer;

2 vaginal cancer

25/5

9.2

14

18% acute G2 dysuria and GI toxicity

9% G3 late GI-toxicity (rectal bleeding)

3 patients died (2 with recurrent cervical cancer, 1 patient with LACC)

1 patient had local recurrence 3.5 years after SBRT

Haas et al. (2012)

6 LACC

20/4

19.5/3

n/a

14

No toxicities

No local recurrence

Molla et al. (2005)

9 endometrial cancer

7 cervical cancer

14/2

20/5

n/a

12.6

No ≥ G3 acute toxicities

Late toxicities:

6% G3 GI-toxicities (rectal bleeding)

6% G1 abdominal pain

38% G1 sexual toxicity (vaginal dryness, synechiae, dyspareunia)

6% recurrence after 12.6 months

Guckenberger et al. (2010)

16 recurrent cervical cancer and endometrial cancer

15/3

92

22

10.5% G4 intestinovaginal fistulae

5.3% G4 small bowel ileus

3-yr OS 34%

3-yr LC 81%

Kemmerer et al. (2013)

11 unresectable endometrial cancer (stage I-III)

30/5

n/a

10

No late toxicity

1-yr FFP 68%

Higginson et al. (2011)

5 (1 endometrial cancer, 2 vaginal cancer, 1 cervical cancer, 1 urothelial carcinoma)

20/5

25/5

16/4

n/a

11

20% G3 rectal bleeding

4 patients died. 1 patient had no evidence of disease

Marnitz et al. (2013)

11 LACC

30/5

48.9

6

No G3 GU and GI acute toxicity

No local recurrences after 6 months

Ito et al. (2019)

6 LACC

19.5/3

21/3

22.5/3

n/a

17

No G3 toxicities

100% LC at last follow-up

1 distant metastasis at last follow-up

Our study (2021)

5 recurrent cervical cancer

2 LACC

3 recurrent vaginal cancer

21.0/4

43.5

9

No G3 toxicities

6 CR

2 PR

2 PD